Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain: A Multi-Center, Randomized, Controlled Trial (RENEU)

NCT07568015 is registered in ClinicalTrials.gov with Brixton Biosciences, Inc. as lead sponsor.

NCT NCT07568015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07568015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain: A Multi-Center, Randomized, Controlled Trial (RENEU)
Lead sponsor
Brixton Biosciences, Inc.
Phase
Not applicable
Overall status
Recruiting
Start date
July 27, 2026
Completion date
November 1, 2029
Enrollment
100 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

greater trochanteric pain syndrome, greater trochanteric pain syndrome of both lower limbs, lateral hip pain